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Background: Cancer stem cells (CSCs) play an important role in 
non–small-cell lung cancer recurrence and metastasis. We sought to 
determine whether CSC-like cells respond differentially to proton 
and photon beam therapies.
Methods: CSC-enriched cells from paclitaxel-resistant human H460 
and A549 cell lines were irradiated with the same relative biologi-
cal effectiveness dose and analyzed for cell viability, clonogenic 
survival, apoptosis, cell migration, cell invasiveness, tumor sphere 
formation, and CSC markers. The intracellular concentration of reac-
tive oxygen species (ROS) was measured before and after irradiation.
Results: Compared with photons, protons caused significantly lower 
cell viability in chemoresistant cells and, in CSC-like cells, signifi-
cantly lower clonogenic survival, invasiveness, and number of tumor 
spheres; less migration and CSC markers (coxsackievirus and adenovi-
rus receptor, β-catenin, and side population cells); more apoptosis; and 
higher ROS level. CSC-like cells contained less than half the ROS lev-
els of parental cancer cells or normal human bronchial  epithelial cells.
Conclusions: CSC-like cells may be more sensitive to irradiation 
with protons than photons. The increased sensitivity could be caused 
by the greater ROS generated by protons. Because chemoresistant 
CSCs play an important role in tumor recurrence, protons may be 
more effective than photons in eliminating recurrent or persistent 
non–small-cell lung cancer.
Key Words: Non–small-cell lung cancer, Cancer stem cells, Treatment 
resistance, Proton therapy, Photon therapy.
(J Thorac Oncol. 2013;8: 1484–1491)
Putative cancer stem cells (CSCs), which have enhanced DNA damage-repair mechanisms to overcome the 
DNA-damaging effects of radiograph radiation,1 are implicated 
in tumor cell resistance to radiotherapy or chemotherapy.2–7 
Treatment strategies targeting CSCs may help to overcome 
this resistance in cancer patients.8 Charged particles with high 
linear-energy transfer, such as neutrons, may be capable of 
overcoming CSC DNA repair, but their severe effect on nor-
mal tissue renders treatment with these particles problematic 
for most radiotherapeutic applications. Like any charged par-
ticle, protons possess a radiation dose deposition characteris-
tic called the Bragg peak.9 It is because of this property that 
proton therapy is able to spare normal tissues surrounding the 
tumor target to a much greater degree than can photon therapy. 
This characteristic may allow dose intensification for cancers 
such as non–small-cell lung cancer (NSCLC) and minimize 
dose-related toxicities to normal tissue.10–12
Because of its promising safety and efficacy profile, 
proton therapy is operational in 39 cancer treatment centers 
around the world, and many more centers are under construc-
tion or being planned. However, the biological efficacy of 
proton versus photon (radiograph) therapy is still poorly under-
stood. The ability of protons to exert cytotoxic damage to cells 
has been considered to be 10% higher than that of photons 
such that the relative biological effectiveness (RBE) of pro-
tons is 1.1, regardless of the cell or tissue type.13,14 This RBE 
value is used routinely to adjust the clinical radiotherapy dose 
with protons as compared with photons. However, this adjust-
ment is a gross oversimplification. Because of their charge 
and mass, protons produce locally higher ionization density 
regions along their tracks than photons do, producing a diffuse 
field of ionization through secondary electrons. Furthermore, 
neutrons produced by high-energy protons have a relatively 
high RBE. These factors may be responsible for observed dif-
ferences in the sublethal damage:cell kill ratio between pro-
tons and photons and suggest that radiation-resistant cells may 
be more likely to be killed by protons than photons.15,16
We recently reported results from our phase II clini-
cal trials of early-stage and locally advanced NSCLC treated 
with dose-escalated proton therapy.11 Our data showed that 
compared with photon therapy, irradiation with protons seems 
to reduce side effects and have high local control. The latter 
regimen might have had better clinical outcomes partially by 
having greater biologic effectiveness than what an RBE of 
1.1 suggests. We hypothesize that the differences in the effec-
tiveness were because of how CSC-like cells respond to pro-
ton therapy and photon therapy. We tested this hypothesis by 
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using a previously established model of CSC-like cells from 
paclitaxel-resistant (chemotherapy resistant) NSCLC cell 
lines.2 We found that protons kill more CSC-like cells than 
photons do at the same radiation dose.
MATERIALS AND METHODS
Cell Lines and Reagents
Human NSCLC cell lines A549 and H460 were 
obtained from the American Type Culture Collection and 
routinely maintained in Roswell Park Memorial Institute 
(RPMI)-1640 medium (Life Technologies, grand Island, 
NY) supplemented with 10% fetal bovine serum, 10,000 U/
ml of penicillin–streptomycin, and 2 mmol/liter of glutamine. 
Normal human bronchial epithelial (NHBE) cells were pur-
chased from Clonetics Corporation (Walkersville, MD) and 
cultured as recommended by the manufacturer. The identi-
ties of these cell lines were validated by short tandem repeat 
profiling (performed by the Characterized Cell Line Core of 
The University of Texas MD Anderson Cancer Center) using 
the AmpFlSTR Identifiler polymerase chain reaction ampli-
fication kit (Applied Biosystems, Foster City, CA) according 
to the manufacturer’s instructions. The short tandem repeat 
profiles for these cell lines matched their known American 
Type Culture Collection fingerprints.
Generation of Treatment-Resistant Cell Lines
We established two CR- and CSC-enriched NSCLC cell 
lines, H460/CR and A549/CR, by repeatedly treating parental 
H460 and A549 cells with paclitaxel to induce chemoresis-
tance, as described previously.2 The cells were initially treated 
with 5 nM paclitaxel, and the surviving cells were then treated 
with increasing doses of up to 100 nM.
Stem cells can efflux Hoechst 33342 (Life Technologies) 
dye by means of verapamil-sensitive adenosine triphosphate 
(ATP)-binding cassette transporters. This classic stem cell 
characteristic is referred to as having a side population (SP). 
For each treatment-resistant cell line, SP cells (H460/CR/SP 
and A549/CR/SP cells) were obtained and sorted serially. We 
refer to these cells as CSC-like cells. Reanalysis of SP cells 
from the cultured SP cells demonstrated enrichment of the SP 
cells and production of non-SP (NSP) cells (H460/CR/NSP 
and A549/CR/NSP cells).2
Irradiation Protocol
Cell irradiation with proton beams was done at the 
Proton Therapy Center at the MD Anderson Cancer Center. 
Cells were irradiated at the center of the spread-out Bragg 
peak modulated to the depth of the cell layer. The irradia-
tion system and biophysical characteristics of proton beams 
have been detailed elsewhere.11,12 For irradiation with photon 
beams, γ-rays from the cobalt-60 machine at MD Anderson 
Cancer Center were used with the same cobalt gray equivalent 
(CgE) on the same day.
Cell Viability Assay
The viability of parental H460 and A549 cell lines, 
treatment-resistant H460 and A549 cell lines, and NHBE 
cells was determined using the sulforhodamine B colorimetric 
assay 4 days after irradiation. Each experiment was done in 
quadruplicate and repeated at least twice.
Clonogenic Assay
For the clonogenic assay, parental H460 and A549 
cell lines and treatment-resistant H460 and A549 cell lines 
(the latter with or without SP cells) were trypsinized, passed 
through a 40-μm sieve, and immediately irradiated at room 
temperature to generate a dose curve of 0, 2, 4, and 8 gy. 
Corresponding control cells were sham irradiated. Colony-
forming assays were begun immediately after irradiation 
by replating the cells into triplicate 100-mm culture dishes 
using the same method described previously.17,18 Colony 
formation was assessed 14 days after irradiation. To deter-
mine survival fractions, counts were normalized using the 
plating efficiency of the unirradiated corresponding control 
cells. Each experiment was done in triplicate and repeated 
at least twice.
Terminal Deoxynucleotidyl Transferase–
Mediated Deoxyuridine Triphosphate-
Biotin Nick End-Labeling Assay
Apoptosis of parental or treatment-resistant H460 cells 
(the latter with or without SP cells) was evaluated 48 hours 
after irradiation by flow cytometry with a terminal deoxy-
nucleotidyl transferase–mediated deoxyuridine triphosphate-
biotin nick end-labeling (TUNEL) kit (Roche Applied Science, 
Indianapolis, IN) by dual color, as previously described.2,17,19 
Three independent experiments were conducted.
Matrigel Cell Migration and Invasion Assay
To determine the invasiveness potential of parental and 
treatment-resistant H460/CR cells, we used the CytoSelect 
24-well cell chemotaxis assay, flourometric format (Cell 
Biolabs, Inc., San Diego, CA) 48 hours after irradiation. The 
assay was performed exactly as described by the manufac-
turer. In brief, cells were starved of serum for 24 hours and 
subsequently seeded into the upper chamber onto a rehydrated 
basement membrane covering a Matrigel (BD Bioscineces, 
San Jose, CA) preparation with a diameter of 8 μm. Cells were 
allowed to invade toward 10% fetal calf serum for 24 hours. 
Cells that invaded to the bottom of the membrane were stained 
and quantified as described in the assay protocol. This assay 
was repeated three times.
Reactive Oxygen Species Analysis
We used flow cytometry with 2’-7’-dichlorofluores-
cein diacetate (H2DCF-DA) staining to determine the level 
of intracellular reactive oxygen species (ROS). Briefly, 
the day before the assay was performed, H460, H460/CR, 
H460/CR/SP, H460/CR/NSP, and NHBE cells were seeded 
at a density of 2 × 105 per well onto 6-well plates overnight. 
The cells were then irradiated with protons or photons at 
0 or 4 gy at different time points. H2DCF-DA was dis-
solved in dimethyl sulfoxide and diluted with prewarmed 
phosphate-buffered saline (PBS) to a final concentration of 
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5 µM. After treatment with radiation at different time points 
(from 6 hours to 9 days), the growth medium was replaced 
with PBS containing H2DCF-DA. After incubation for 40 
minutes at 37°C, the cells were returned to a prewarmed 
growth medium and incubated at 37°C for 10 minutes. 
Cells were trypsinized and washed with prewarmed PBS 
once. The samples were then subjected to a flow cytometric 
assay using a Caliber fluorescence-activated cell sorter (BD 
Biosciences, San Jose, CA). These were performed at the 
Flow Cytometry and Cellular Imaging Core Facility at MD 
Anderson Cancer Center. All experiments were performed 
at least twice.
Tumor Sphere Formation Assay
H460/CR/SP cells were suspended in 0.8% methylcel-
lulose-based serum-free medium supplemented with 20 ng/ml 
epidermal growth factor, 20 ng/ml basic fibroblast growth 
factor, and 4 µg/ml insulin and plated at 2000 cells/ml in 
ultralow-attachment 24-well plates (Corning, Tewksbury, MA). 
The medium was replaced or supplemented with fresh growth 
factors twice a week. To assess the self-renewing potential 
of the cells, first-generation spheres were collected by gentle 
centrifugation, dissociated into single-cell suspensions, and 
filtered and cultured under the stem cell–selective conditions. 
The same procedures were repeated with the second- and 
third-generation spheres. Third-generation spheres were used 
in our experiments. A total of 1000 cells per ml was plated 
in ultralow-attachment 96-well plates (Corning, Tewksbury, 
MA) in 200 µl of growth medium cultured under the stem 
cell–selective conditions. The cells were then irradiated with 
protons or photons at 0 or 4 gy. After 2 weeks of culture, 
tumor spheres were visualized with a phase-contrast micro-
scope and counted in each well as described previously.2
Flow Cytometric Assay of Coxsackievirus 
and Adenovirus Receptor Expression,  
β-Catenin Expression, and SP Cells
Ninety-six hours (4 days) after irradiation of H460/
CR/SP cells at 4 gy, we used flow cytometry to determine 
coxsackievirus and adenovirus receptor (CAR) and β-catenin 
expression levels as well as the percentage of SP cells.2,17,19
Statistical Analysis
Data are expressed as means and 95% confidence 
 intervals, some are expressed as means ± SD. Analysis of vari-
ance and Student’s t tests (two-tailed) were performed to test 
for significant differences. A difference was considered statis-
tically significant when the p value was 0.05 or less.
RESULTS
Proton Therapy Decreases Cell Viability 
More So Than Photon Therapy Does
To detect differences in the effects of the proton and 
photon modalities, we determined cell viability by sulforho-
damine B colorimetric assay in NSCLC cell lines H460, 
H460/CR, A549, A549/CR and in NHBE cells on the fourth 
day after treatment with radiation doses up to 8 gy at the same 
CgE (RBE = 1.1). We observed significantly weaker cell-kill-
ing effects of photons versus protons in the treatment-resistant 
cell lines (H460/CR and A549/CR) but not in the parental 
nonresistant cell lines or the NHBE cells (Fig. 1).
Proton Therapy Induces Lower Clonogenic 
Survival Than Photon Therapy Does
To determine whether proton therapy affects clonogenic 
survival in cancer cells differently than photon therapy does, 
we performed clonogenic formation assays with parental and 
treatment-resistant cell lines as well as with the putative stem 
cell fraction of the resistant cells identified as SP by Hoeschst 
dye exclusion. On the 14th day after irradiation with a dose of 
up to 8 gy, colony formation of CSC-like cells (H460/CR/SP 
and A549/CR/SP cells) was significantly less with protons 
than photons (Fig. 2).
We also found that compared with photon radiation, clo-
nogenic survival was significantly lower in treatment-resistant 
cells irradiated with protons at 4 gy (p < 0.05 for both lines). 
However, no significant differences were seen for paren-
tal nonresistant cells or for resistant cells with NSPs. Taken 
together, these results indicate that protons better target CSC-
like cells than photons do.
Proton Therapy Induces Higher Levels of 
Apoptosis Compared with Photon Therapy
To investigate whether the enhanced cell killing by pro-
ton radiation occurred through an apoptotic mechanism, we 
quantified apoptotic cells using the TUNEL assay in H460, 
H460/CR, H460/CR/SP, and H460/CR/NSP cells at 48 hours 
after radiation. Both modalities induced marked increases in 
apoptosis in a dose-dependent manner in all four cell lines 
(Fig. 3A). However, protons induced significantly greater 
levels of apoptosis in H460/CR cells and in CSC-like cells 
(H460/CR/SP cells) than photons did.
Proton Therapy Reduces Migration 
and Invasiness of CSC-Like Cells More 
Than Photon Therapy Does
To assess whether the differential effects of proton and 
photon irradiation on apoptosis in CSC-like cells we observed 
were reflected by cell motility, we examined the migration of 
malignant cells 48 hours after irradiation using the chemotaxis 
assay in H460, H460/CR, H460/CR/SP, H460/CR/NSP cells. 
In general, both proton and photon radiation suppressed migra-
tion in a dose-dependent manner, although we noticed a trend 
toward an increase in migration at lower doses (0.5 and 1 gy) 
of photon irradiation (Fig. 3B). Compared with photons, pro-
tons at comparable doses significantly reduced migration in 
the CSC-like H460/CR/SP cells.
We next focused on changes in the invasive capability 
of cancer cells after irradiation using the Matrigel invasion 
assay the same four cell lines. The results mirrored our obser-
vations for cell migration (Fig. 3C). Thus, compared with pho-
tons, protons suppressed both the migration and invasiveness 
potential of the cancer cells even at lower radiation doses.
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Proton Therapy Induces Higher ROS 
Levels Than Photon Therapy Does
Radiation is cytotoxic because it induces double-
stranded DNA breaks from ROS produced from secondary 
ionization of molecules.20 To determine whether the differ-
ential cytotoxic effects of protons and photons in CSC-like 
cells we observed were because of differences in ROS pro-
duction, we measured the intracellular concentrations of pro-
oxidants by using H2DCF-DA staining by flow cytometry. 
Baseline measurements showed lower ROS levels in parental 
H460 cells than in normal NHBE cells (Fig. 4A, left). We also 
found lower baseline ROS levels in CSC-like H460/CR/SP 
cells than in H460/CR or H460/CR/NSP cells (Fig. 4A, right).
given these observations, we were interested to see 
whether there were differences in the production of ROS 
after proton or photon radiation. We measured ROS levels 
in H460, H460/CR, H460/CR/SP, and NHBE cell lines at 48 
hours after irradiation with 0, 2, 4, 8 gy (RBE = 1.1). Both 
modalities induced ROS levels increases in a dose-dependent 
manner in all four cell lines. Protons with 4 gy induced 
significantly higher ROS levels than photons did in H460/
CR cells (3.8-fold versus 2.6-fold) and H460/CR/SP cells 
(3.4-fold versus 2.1-fold), but not in H460 (3.6-fold versus 
3.0-fold) and NHBE cells (1.2-fold versus 1.1-fold). We fur-
ther measured ROS levels in H460 and H460/CR/SP cells 
for up to 9 days (216 hours) after irradiation 4 gy. Protons 
induced significantly higher ROS levels than photons did in 
H460/CR/SP cells at almost all time points, but in the parental 
H460 cells at 7 days (168 hours) only (Fig. 4D). These results 
suggest that protons induce greater ROS levels in CSCs and 
thus have great cytotoxicity than  photons do.
Proton Therapy Results in Less Tumor Sphere 
Formation Compared with Photon Therapy
We tested the ability of proton therapy and photon ther-
apy to affect the tumor sphere formation of CSC-like H460/
CR/SP cells grown in suspension cultures using serum-free 
medium under stem cell–selective conditions.2 Both types of 
FIGURE 1.  Protons have greater cell-killing effects than photons in treatment-resistant NSCLC cell lines but not in normal cells. 
H460, H460/CR, A549, A549/CR, and NHBE cell lines were irradiated at the indicated doses (0, 1, 2, 4, and 8 Gy) at the same 
CGE (RBE = 1.1). Cell viability was determined by the sulforhodamine B assay on the fourth day after irradiation. Each experi-
ment was done in quadruplicate and repeated at least twice. Values are means ± SD. *p < 0.05 versus protons at the same dose, 
as determined using paired two-sided Student’s t test. CR, chemotherapy resistant; NHBE–, normal human bronchial epithelial; 
NSCLC, non–small-cell lung cancer; CGE, cobalt gray equivalent; RBE, biological effectiveness.
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radiation significantly inhibited tumor sphere formation, but 
more so with proton radiation (17 ± 2 versus 32 ± 5; Fig. 5A, B).
Proton Therapy Results in Lower CAR and 
β-Catenin Expression Levels and Lower 
Percentage of SP Cells Compared with 
Photon Therapy in CSC-Like Cells
Finally, we used flow cytometry to measure the expres-
sion levels of the CSC markers CAR, β-catenin, and SP 96 
hours after irradiation at 4 CgE in H460/CR/SP cells. Only 
protons significantly reduced the expression of CAR (80.6% 
versus 92.1%) and β-catenin (20.3% versus 32.6%; Fig. 5C) 
as well as the percentage of SP cells (39.5% versus 50.1%; 
Fig. 5D) in CSC-like cells.
DISCUSSION
In this article, we investigated the biologic differences 
between proton beam therapy and photon beam therapy and 
determined whether protons (delivered with an RBE of 1.1) and 
photons have differential cytotoxic effects on CSC-enriched 
CSC-like cells as well. What we found was consistent with our 
previous data that protons kill more CSC-like cells than photons 
do at the same radiation dose. Regardless of the assay we used 
(for cell viability, clonogenic survival, apoptosis, cell migra-
tion or invasiveness, or tumor sphere formation), our current 
results indicate that protons have a greater biologic effect than 
what an RBE of 1.1 seems to indicate. Why CSC-like cells are 
more likely to be killed by protons is not entirely clear. Our 
data suggested that ROS generation was significantly higher in 
CSC-like cells with proton therapy than with photon therapy. 
Whether this is difference is related to the high ionization den-
sity of protons in the cells is also unclear.
ROS regulates a broad array of signal transduction path-
ways in various biological processes, including gene expres-
sion, cell growth, differentiation, and apoptosis. ROS caused 
by high glucose, angiotensin, tumor necrosis factor-α, irradia-
tion, or other stressors enhances the apoptosis of various tumor 
cells. Effective management of ROS in normal tissue stem cells 
may contribute to their fitness and hence the life span of the 
organism.21,22 But what happens when the machinery for ROS 
management that is used by normal stem cells is hijacked by 
CSCs to maintain cellular fitness? The work of Phillips et al.23 
showed that cancer-initiation cells are more resistant to radia-
tion than are cells grown as monolayer cultures and that ROS 
levels are lower in cancer-initiation cells than in monolayer 
FIGURE 2.  Protons better target CSC-like cells in treatment-resistant NSCLC compared with photons. Clonogenic survival 
assay of H460, H460/CR, H460/CR/SP, H460/CR/NSP, A549, A549/CR, A549/CR/SP, and A549/CR/NSP cells on the 14th day 
after irradiation up to 8 Gy at the same CGE (RBE = 1.1). Values are means (95% CI) of triplicate assay results as determined 
using paired two-sided Student’s t test. *p < 0.05 versus proton therapy at the same dose. CR, chemotherapy resistant; NSCLC, 
non–small-cell lung cancer; CGE, cobalt gray equivalent; RBE, biological effectiveness; SP, side population; NSP, nonside popula-
tion; CSC, cancer stem cell; CI, confidence interval.
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cultures after irradiation. The most recent findings in this area 
support and extend this concept. Diehn et al.1 demonstrated that 
human and mouse breast CSCs, similar to their normal tissue 
counterparts, maintain low levels of ROS that afford radiopro-
tection, providing a possible explanation for tumor recurrence 
with photon therapy. Consistent with the idea of ROS being 
critical mediators of ionizing radiation–induced cell killing, 
CSCs were found to develop less DNA damage than nontu-
morigenic cells did and were more likely to be spared after 
photon irradiation. Lower ROS levels in CSCs are associated 
with increased expression of free radical scavenging systems.1 
Our results are consistent with these reports. Further studies 
are needed to examine gene expression profiles of CSCs and 
non-CSCs in treatment-resistant NSCLC to determine whether 
the former have stronger antioxidant defense systems.
Pietro et al.24 demonstrated that compared with photon 
radiation, proton radiation significantly increased the intracel-
lular level of ROS in CSCs and that it altered cell structures 
such as membranes, caused DNA double-stranded breaks, 
and significantly increased apoptosis and intracellular levels 
of ROS in the MCF7, PC3, and Ca301D cancer cell lines. 
Finnberg et al.15 further demonstrated that proton therapy trig-
gers DNA damage and apoptosis in vivo more efficiently than 
photon therapy does and that the apoptotic responses varied 
greatly between proton and photon therapy in a tissue- and 
dose-dependent manner. Moreover, the work by Ogata et al.16 
A
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FIGURE 3.  Compared with photons, protons induce a higher level of apoptosis and a greater reduction in cell migration and 
invasion in a dose-dependent manner in CSC-like NSCLC cells. A, Percentage of apoptotic cells as determined with TUNEL assay 
by flow cytometry in H460, H460/CR, H460/CR/SP, H460/CR/NSP cells 48 hours after irradiation (0, 0.5, 1, 2, 4 Gy) at the same 
CGE (RBE = 1.1). Migration (B) and invasiveness (C) of the same cell lines 48 hours after irradiation (0, 0.5, 1, 2, 4 Gy) with the 
same doses at the same CGE (RBE = 1.1) by 96-well cell migration and invasion assay (fluorometric format). Values are means 
(95% CI) of three independent experiments. *p < 0.05 versus protons at the same dose, as determined using paired two-sided 
Student’s t test. CR, chemotherapy resistant; RFU, relative fluorescence unit; NSCLC, non–small-cell lung cancer; CGE, cobalt 
gray equivalent; RBE, biological effectiveness; SP, side population; NSP, nonside population; CSC, cancer stem cell; CI, confi-
dence interval; TUNEL, terminal deoxynucleotidyl transferase–mediated deoxyuridine triphosphate-biotin nick end-labeling.
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suggest that at lower doses, proton irradiation suppresses 
metastatic potential whereas photon irradiation promotes cell 
migration and invasive capabilities. The authors also provided 
preclinical evidence that proton therapy is superior to conven-
tional photon therapy in preventing the metastasis of irradi-
ated malignant tumor cells. Our own data on cell migration 
and invasion support these observations.
There are several limitations to our study. First, only 
CSC-like treatment-resistant cell lines generated from two 
parental cell lines (H460 and A549) were tested. In addition, 
only H460 cell line series were used for the test of apoptosis, 
cell migration/invasion, ROS levels, sphere formation, and 
CSC marker expression. It is possible that different cell lines 
may have varied sensitivities to proton beam because of differ-
ent genetic backgrounds. Second, limited radiation doses and 
therapy designs were conducted because of limited machine 
time and biological safety issues in the patient treatment facil-
ity. We originally planned to use more cell lines and add in 
vivo study to validate our results. Thus, this report focuses on 
hypothesis generation; further studies are needed to validate 
these observations.
We have shown for the first time that treatment-resistant 
CSC-like cell lines are more sensitive to protons than photons 
at the same RBE. The greater effects of proton therapy on CSC-
like cells could be because of the higher generation of ROS by 
protons than photons. Assuming that treatment-resistant CSCs 
have a role in the tumor recurrence, protons may be more effec-
tive than photons in eliminating recurrent or persistent NSCLC. 
Further laboratory studies, particularly in vivo experiments and 
clinical evaluation of ongoing and planned randomized trials 
at various disease sites, are needed to confirm this hypothesis.
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FIGURE 4.  Protons induce higher ROS levels than photons do in CSC-like NSCLC cells. A, Representative histograms of intracel-
lular ROS level in H460, H460/CR, H460/CR/SP, H460/CR/NSP, and NHBE cells. B, Representative histograms of ROS generation 
at 48 hours after irradiation at 4 Gy. C, Corresponding quantitative comparison of ROS generation. D, Quantitative comparison of 
ROS generation in H460 and H460/CR/SP cells for up to 9 days after irradiation at 4 Gy. Values are means (95% CIs). All experi-
ments were performed at least three times. *p < 0.05 versus proton at the same dose, as determined using paired two-sided 
Student’s t test. CR, chemotherapy resistant; NHBE, normal human bronchial epithelial; NSCLC, non–small-cell lung cancer; ROS, 
reactive oxygen species; SP, side population; NSP, nonside population; CSC, cancer stem cell; CI, confidence interval.
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FIGURE 5.  Protons cause a greater reduc-
tion than photons of sphere formation of 
CSC-like cells and CSC marker expression 
in CSC-like NSCLC cells. A, Phase-contrast 
microscopy images of tumor spheres of 
H460/CR/SP cells after irradiation at 4 Gy 
under stem cell–selective conditions for 
2 weeks. B, Corresponding quantitative 
comparison of number of tumor spheres. 
C, Expression of CSC markers CAR and 
β-catenin in H460/CR/SP cells. D, The per-
centage of SP cells in H460/CR/SP cells as 
measured by flow cytometry 96 hours after 
irradiation. Values are means (95% CIs). All 
experiments were performed at least three 
times. *p < 0.05 versus protons at the same 
dose, as determined using paired two-sided 
Student’s t test. CR, chemotherapy resis-
tant; SP, side population; CSC, cancer stem 
cell; CI, confidence interval; NSCLC, non–
small-cell lung cancer; CAR, coxsackievirus 
and adenovirus receptor.
